Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.58 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.54 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 5/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485077 | 0.89 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL14065666 | 0.89 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL14065670 | 0.89 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL18633064 | 0.89 | DPP7 (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL18714213 | 0.87 | DPP7 (0.56) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL2115366 | 0.84 | GSR (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL2115368 | 0.84 | GSR (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL17510190 | 0.84 | GSR (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL7781619 | 0.84 | GSR (0.58) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL1641744 | 0.84 | GSR (0.58) | DPP8DPP9DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3431140-B1 | NERVE REGENERATION-INDUCING MATERIAL | TAZUKE KOFUKAI (JP) | 2024-03-27 | — | — | EP | claimed |
| US-20210283304-A1 | NERVE REGENERATION-INDUCING MATERIAL | TAZUKE KOFUKAI (JP) | 2021-09-16 | — | — | US | claimed |
| US-11052174-B2 | Nerve regeneration-inducing material | Kofukai, Tazuke (JP) | 2021-07-06 | — | — | US | claimed |
| US-20200268931-A1 | BRAIN DAMAGE RECOVERY MATERIAL | TAZUKE KOFUKAI (JP) | 2020-08-27 | — | — | US | claimed |
| US-20190083678-A1 | NERVE REGENERATION-INDUCING MATERIAL | TAZUKE KOFUKAI (JP) | 2019-03-21 | — | — | US | claimed |
| EP-3431140-A1 | NERVE REGENERATION-INDUCING MATERIAL | Tazuke Kofukai (JP) | 2019-01-23 | — | — | EP | claimed |
| EP-0914832-B1 | THERAPEUTIC MATERIAL FOR PERIODONTOSIS | KURARAY CO (JP) | 2006-11-22 | — | — | EP | claimed |
| EP-0712635-B1 | MEDICAL POLYMER GEL | KURARAY CO (JP) | 2003-05-02 | — | — | EP | claimed |
| US-5658592-A | HEAT RESISTANCE, BIOCOMPATIBILITY, TRANSPARENCY; WOUND DRESSINGS | KURARAY CO., LTD. (JP) | 1997-08-19 | — | — | US | claimed |
| EP-3431140-B1 | NERVE REGENERATION-INDUCING MATERIAL | TAZUKE KOFUKAI (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-20210283304-A1 | NERVE REGENERATION-INDUCING MATERIAL | TAZUKE KOFUKAI (JP) | 2021-09-16 | — | — | US | disclosed |
| US-11052174-B2 | Nerve regeneration-inducing material | Kofukai, Tazuke (JP) | 2021-07-06 | — | — | US | disclosed |
| US-20200268931-A1 | BRAIN DAMAGE RECOVERY MATERIAL | TAZUKE KOFUKAI (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10307996-B2 | Nano thin-film transfer sheet, method for manufacturing nano thin-film transfer sheet, and method for transferring nano thin-film layer into adherend | HITACHI CHEMICAL COMPANY, LTD (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20050164980-A1 | Hyaluronic acid modification product | CHUGAI SEIYAKU KABUSHIKI KAISYA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1496037-A1 | HYALURONIC ACID MODIFICATION PRODUCT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6200595-B1 | MIXTURE OF ANIONS AND CATIONS | KURARAY CO., LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-0951914-A2 | Medical adhesive | KURARAY CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0914832-A1 | THERAPEUTIC MATERIAL FOR PERIODONTOSIS | KURARAY CO., LTD. (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5658592-A | HEAT RESISTANCE, BIOCOMPATIBILITY, TRANSPARENCY; WOUND DRESSINGS | KURARAY CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164980-A1 | Hyaluronic acid modification product | CD44, HAAO, HAO1 | DPP8 3674/4885DPP9 2989/4885DPP7 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.